Second-Line Trastuzumab Plus Ramucirumab/Paclitaxel Elicits Activity in HER2+ Gastric/GEJ Cancer

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Related Keywords

South Korea ,Republic Of Korea ,Trastuzumab Herceptin , ,Gastric Cancer ,Gastroesophageal Junction Adenocarcinoma ,Ther2 ,Trastuzumab Deruxtecan ,Her2 Positive Gastric Or Gastroesophageal Junction Gej Cancer ,Trastuzumab Containing Regimen ,Journal Of Clinical Oncology ,The Phase 1 2 Her Ram Study Nct04888663 ,